Trial Profile
An Open-label, Long Term Extension Study of MT-8554 in Postmenopausal Women Experiencing Moderate to Severe Vasomotor Symptoms Who Completed Study MT-8554-A01
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2018
At a glance
- Drugs Elismetrep (Primary)
- Indications Vasomotor symptoms
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 25 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2018 New trial record